Rafael Alfonso Figueroa Díaz

Q: What Schools Are Affiliated With Rafael Alfonso Figueroa Díaz

Rafael Alfonso Figueroa Díaz is affiliated with the following schools: University of Alberta, McMaster University, University of Glasgow

Rafael Alfonso Figueroa Díaz's AcademicInfluence.com Rankings

Medical

#3073

World Rank

#3525

Historical Rank

Cardiology

#310

World Rank

#319

Historical Rank

Pharmacology

#363

World Rank

#414

Historical Rank

medical Degrees

Rafael Alfonso Figueroa Díaz

Philosophy

#8882

World Rank

#12345

Historical Rank

Logic

#5893

World Rank

#7341

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Rafael Alfonso Figueroa Díaz's Degrees

Doctorate Medicine Stanford University

Why Is Rafael Alfonso Figueroa Díaz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Rafael Alfonso Figueroa Díaz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Dabigatran versus warfarin in patients with atrial fibrillation. (2009) (8312)
Apixaban versus warfarin in patients with atrial fibrillation. (2011) (6217)
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Apixaban in patients with atrial fibrillation. (2011) (1889)
Spironolactone for heart failure with preserved ejection fraction. (2014) (1835)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. (2015) (1755)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease (2017) (1499)
Basal insulin and cardiovascular and other outcomes in dysglycemia. (2012) (1458)
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. (2013) (1457)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (2019) (1256)
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. (2019) (1180)
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study (2016) (1172)
ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION (1992) (920)
Apixaban with antiplatelet therapy after acute coronary syndrome. (2011) (872)
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey (2011) (832)
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. (2012) (814)
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study (2006) (797)
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. (2008) (776)
Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study (2003) (743)
Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study (2017) (738)
Urinary sodium and potassium excretion, mortality, and cardiovascular events. (2014) (723)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial (2015) (709)
The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study (2017) (703)
Association of urinary sodium and potassium excretion with blood pressure. (2014) (676)
Cardiovascular risk and events in 17 low-, middle-, and high-income countries. (2014) (663)
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. (2005) (643)
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. (2016) (621)
Effect of ramipril on the incidence of diabetes. (2006) (569)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) (558)
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study (2020) (555)
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. (2010) (549)
Effect of nesiritide in patients with acute decompensated heart failure. (2011) (516)
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. (2016) (499)
Metabolic Modulation of Acute Myocardial Infarction The ECLA Glucose-Insulin-Potassium Pilot Trial (1998) (477)
Darapladib for preventing ischemic events in stable coronary heart disease. (2014) (475)
Treatment of anemia with darbepoetin alfa in systolic heart failure. (2013) (439)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. (2020) (424)
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. (2014) (391)
Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study (2017) (389)
Risk Factors for Acute Myocardial Infarction in Latin America: The INTERHEART Latin American Study (2007) (375)
Dronedarone in high-risk permanent atrial fibrillation. (2011) (368)
Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies (2016) (366)
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina (1998) (351)
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study (2020) (324)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial (2019) (311)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. (1999) (311)
Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. (2013) (279)
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. (2015) (276)
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. (2020) (266)
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data (2016) (266)
Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. (2019) (249)
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. (2011) (243)
Metabolic modulation of acute myocardial infarction. (2001) (236)
Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial (2004) (229)
Blood-pressure reduction and cardiovascular risk in HOPE study (2001) (221)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. (2020) (220)
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. (2013) (217)
Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. (1998) (210)
Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study (2018) (207)
Significance of Smoking in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction Experience Gleaned From the International Tissue Plasminogen Activator/Streptokinase Mortality Trial (1993) (199)
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial (2018) (197)
Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. (2017) (190)
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. (2016) (185)
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. (2010) (173)
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. The Investigators of the International Tissue Plasminogen Activator/Streptoki (1993) (169)
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (2015) (166)
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. (2010) (163)
Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (2013) (162)
Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONT (2010) (156)
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide (2018) (156)
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. (1996) (155)
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. (2004) (154)
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. (1999) (154)
Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study (2015) (153)
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. (2008) (153)
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. (2016) (145)
Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. (1995) (142)
Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction ☆ (2006) (140)
Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study (2016) (137)
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. (2007) (137)
APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* (2011) (136)
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial (2009) (135)
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) (2020) (134)
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. (2018) (134)
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. (2017) (133)
Effect of Telmisartan on Renal Outcomes (2009) (127)
Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction (2009) (127)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study (2020) (121)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. (2019) (119)
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. (2006) (115)
The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression (2013) (113)
Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. (2013) (111)
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. (2015) (100)
Effect of Alirocumab on Mortality After Acute Coronary Syndromes (2019) (99)
Penetrance of polygenic obesity susceptibility loci across the body mass index distribution: an update on scaling effects (2017) (95)
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. (2020) (94)
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. (2016) (92)
The Effect of Chromosome 9p21 Variants on Cardiovascular Disease May Be Modified by Dietary Intake: Evidence from a Case/Control and a Prospective Study (2011) (91)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina (2001) (83)
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial (2020) (78)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial (2020) (78)
Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study (2018) (77)
Wealth and cardiovascular health: a cross-sectional study of wealth-related inequalities in the awareness, treatment and control of hypertension in high-, middle- and low-income countries (2016) (76)
Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study (2011) (76)
Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study (2019) (76)
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. (2006) (75)
Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study (2018) (70)
Global differences in lung function by region (PURE): an international, community-based prospective study. (2013) (70)
The association between ownership of common household devices and obesity and diabetes in high, middle and low income countries (2014) (69)
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome (2019) (69)
Apixaban Compared with Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the ARISTOTLE Trial (2015) (69)
Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. (2021) (68)
Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. (2020) (68)
Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus (2017) (67)
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. (2020) (65)
Associations of outdoor fine particulate air pollution and cardiovascular disease in 157 436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. (2020) (64)
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. (2012) (61)
Re-Ly study of stroke prevention in atrial fibrillation Dabigatren versus warfarin in patients with atrial fibrillation N Engl J Med 2009; 361.10: 1056 (2009) (61)
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). (2009) (61)
Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study (2016) (60)
Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES (2019) (56)
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. (2020) (52)
Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. (2014) (51)
Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. (2001) (50)
Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. (2019) (50)
Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. (2013) (50)
Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. (2020) (50)
Effect of Ejection Fraction on Clinical Outcomes in Patients treated with Omecamtiv Mecarbil in GALACTIC-HF. (2021) (49)
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease (2020) (49)
Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries. (2019) (48)
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis (2019) (48)
Tobacco control environment: cross-sectional survey of policy implementation, social unacceptability, knowledge of tobacco health harms and relationship to quit ratio in 17 low-income, middle-income and high-income countries (2017) (46)
Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world (2017) (46)
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial (2019) (46)
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. (2003) (46)
Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events (2013) (45)
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. (2019) (45)
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome (2020) (45)
Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study (2021) (44)
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials (2020) (44)
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. (2006) (44)
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction☆ (2004) (44)
Secondary CV Prevention in South America in a Community Setting: The PURE Study. (2017) (42)
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis (2021) (42)
Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. (2001) (40)
Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study (2010) (40)
Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. (2021) (40)
Clinical predictors of in-hospital prognosis in unstable angina: ECLA 3. The ECLA Collaborative Group. (1999) (40)
Psychosocial factors and obesity in 17 high-, middle- and low-income countries: the Prospective Urban Rural Epidemiologic study (2015) (38)
Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease (2016) (38)
Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes (2010) (37)
White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries (2020) (37)
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. (2004) (37)
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) (2020) (37)
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. (2009) (36)
Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). (2009) (35)
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. (2020) (35)
Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population (2015) (34)
Obesity genes and risk of major depressive disorder in a multiethnic population: a cross-sectional study. (2015) (34)
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) (2013) (33)
The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. (2020) (32)
Myocardial viability for decision-making concerning revascularization in patients with left ventricular dysfunction and coronary artery disease: a meta-analysis of non-randomized and randomized studies. (2015) (31)
After Correcting for Worse Baseline Characteristics, Women Treated With Thrombolytic Therapy for Acute Myocardial Infarction Have the Same Mortalit and Morbidit as Men Except for a Higher Incidence of Hemorrhagic Stroke (1993) (31)
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. (2021) (31)
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes (2019) (30)
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol (2021) (29)
Assessing global risk factors for non-fatal injuries from road traffic accidents and falls in adults aged 35–70 years in 17 countries: a cross-sectional analysis of the Prospective Urban Rural Epidemiological (PURE) study (2015) (29)
Effects of blood pressure and lipid lowering on cognition (2019) (29)
Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI) (2020) (29)
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. (2010) (28)
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. (2019) (26)
Association of Urinary Sodium Excretion With Blood Pressure and Cardiovascular Clinical Events in 17,033 Latin Americans. (2016) (26)
Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial: Findings From the Acute Study Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) (2013) (26)
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19 (2021) (26)
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. (2016) (26)
Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). (2018) (25)
Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration (2018) (25)
Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF)™ Trial (2006) (25)
Risk Factors for Acute Myocardial Infarction in Latin America (2007) (24)
Impact of social isolation on mortality and morbidity in 20 high-income, middle-income and low-income countries in five continents (2021) (24)
Associations of unprocessed and processed meat intake with mortality and cardiovascular disease in 21 countries [Prospective Urban Rural Epidemiology (PURE) Study]: a prospective cohort study. (2021) (24)
Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. (2014) (23)
The ridogrel versus aspirin patency trial (rapt) (1992) (23)
HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression (2020) (22)
Left ventricular assessment in myocardial infarction: the VALIANT registry. (2005) (21)
Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level (2020) (21)
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial (2020) (21)
Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial (2018) (20)
Association of nut intake with risk factors, cardiovascular disease, and mortality in 16 countries from 5 continents: analysis from the Prospective Urban and Rural Epidemiology (PURE) study. (2020) (20)
Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries (2020) (19)
Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study (2020) (19)
Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population (2013) (19)
Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes—Prespecified Analyses of ODYSSEY OUTCOMES (2018) (18)
Safety, Tolerability and efficacy of Rapid Optimization, helped by NT‐proBNP and GDF‐15, of Heart Failure therapies (STRONG‐HF): rationale and design for a multicentre, randomized, parallel‐group study (2019) (17)
The Effect of Chromosome 9 p 21 Variants on Cardiovascular Disease May Be Modified by Dietary Intake : Evidence from a Case / Control and a Prospective Study (2011) (17)
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). (2009) (16)
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol (2021) (15)
Does greater individual social capital improve the management of hypertension? Cross-national analysis of 61 229 individuals in 21 countries (2017) (15)
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. (2020) (15)
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 (2015) (14)
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. (2021) (14)
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. (2020) (14)
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19 (2021) (14)
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. (2006) (14)
Effect of Insulin Glargine and n-3 FA on Carotid Intima-Media Thickness in PeopleWithDysglycemiaatHighRiskfor Cardiovascular Events The Glucose Reduction and Atherosclerosis Continuing Evaluation Study ( ORIGIN-GRACE ) (2013) (13)
Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit (2011) (13)
Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome (2020) (13)
Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome (2015) (13)
Cardiovascular Outcomes With Alirocumab After Acute Coronary Syndrome: Results of the Odyssey Outcomes Trial (2018) (12)
Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. (2017) (12)
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. (2021) (11)
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment (2021) (11)
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. (2019) (11)
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial (2018) (11)
Outcome of Thrombolytic Therapy in Relation to Hospital Size and Invasive Cardiac Services (1994) (10)
Characteristics, clinical course, and in-hospital mortality of non-insulin-dependent diabetic and nondiabetic patients with acute myocardial infarction in Argentina. (1997) (9)
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants (2021) (8)
Reduction in Acute Limb Ischemia with Rivaroxaban versus Placebo in Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD. (2021) (8)
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. (2022) (8)
Risk of cardiovascular events associated with positive serology for Chagas: a systematic review. (2012) (8)
Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial (2022) (8)
Colchicine and COVID‐19 (2020) (7)
Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology (2016) (7)
Efficacy and safety of dabigatran versus warfarin from the RE-LY trial (2018) (7)
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline (2020) (7)
Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. (1994) (6)
TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54 (2015) (6)
2387Recurrent cardiovascular events and mortality in relation to antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease (MINOCA) (2019) (6)
Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study. (2021) (6)
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab (2022) (6)
Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): A Case–Control Study (2020) (6)
Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study (2021) (5)
International differences in patients, care, and outcomes associated with acute myocardial infarction: the hero-2 trial (2002) (5)
Heart failure and/or left ventricular systolic dysfunction complicating myocardial infarction is common and accounts for the majority of in-hospital myocardial infarction mortality: Results of the VALIANT registry (2003) (5)
Thrombocytopenia in a large, international trial of the GP IIb/IIIa inhibitor eptitibatide in patients with acute coronary syndromes (1998) (5)
The ODYSSEY OUTCOMES Trial (2019) (5)
Myocardial Protection During Acute Myocardial Infarction: The Need for a Simple Large Randomized Trial with GIK (2000) (4)
Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT (2021) (4)
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. (2020) (4)
Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial (2020) (4)
The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges (2022) (4)
BASELINE CHARACTERISTICS FROM THE CARDIOVASCULAR OUTCOMES TRIAL OF OMECAMTIV MECARBIL, GALACTIC-HF (GLOBAL APPROACH TO LOWERING ADVERSE CARDIAC OUTCOMES THROUGH IMPROVING CONTRACTILITY IN HEART FAILURE) (2020) (3)
Omecamtiv Mecarbil in Chronic HeartFailure With Reduced Ejection Fraction (3)
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. (2020) (3)
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. (2022) (3)
Current Status and Future Strategies for Cardiovascular Disease in Argentina. (2019) (3)
Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study (2017) (3)
Thrombosis and antithrombotic therapy Ischaemic risk and efficacy of ticagrelor in relation to time from P 2 Y 12 inhibitor withdrawal in patients with prior myocardial infarction : insights from PEGASUS-TIMI 54 (2016) (3)
EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL (2020) (3)
Low-dose colchicine in patients treated with percutaneous coronary interventions for myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) (2020) (3)
USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA (2017) (2)
Alirocumab after acute coronary syndrome in patients with a history of heart failure (2021) (2)
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. (2022) (2)
Rationale , Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s ( COMPASS ) Trial (2017) (2)
Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. (2022) (2)
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. (2022) (2)
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes (2022) (2)
P1226Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES (2019) (2)
Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial (2020) (2)
Left Ventricular Assessment in Myocardial Infarction (2013) (2)
ALIROCUMAB AND CARDIOVASCULAR OUTCOMES IN WOMEN AFTER AN ACUTE CORONARY SYNDROME: AN ODYSSEY OUTCOMES TRIAL ANALYSIS (2020) (2)
Glucose-Insulin-Potassium Therapy in Patients With STEMI—Reply (2008) (2)
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: insights from the GALACTIC‐HF trial (2023) (2)
Prognostic Impact of Cardiovascular versus Noncardiovascular Hospitalizations in Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT. (2022) (1)
International differences in patients, care and outcomes associated with acute myocardial infarction (AMI): the HERO-2 trial (2003) (1)
Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab. (2022) (1)
Corrigendum to ‘Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED‐HF): a Phase III, anaemia correction, morbidity–mortality trial’ [Eur J Heart Fail 2009;11:795–801] (2010) (1)
864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED (2022) (1)
Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial (2023) (1)
PATIENTS WITH ACUTE CORONARY SYNDROME, ELEVATED ATHEROGENIC LIPOPROTEINS, AND PRIOR CORONARY ARTERY BYPASS GRAFTING DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL (2019) (1)
Have international guidelines failed? International variation in the treatment of acute MI: results of the VALIANT trial (2004) (1)
Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety? (2020) (1)
944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up (2020) (1)
Impact of known and newly diagnosed diabetes mellitus after a myocardial infarction (2003) (1)
Abstract 15281: Triglyceride Levels and Cardiovascular Outcomes After Acute Coronary Syndrome: Insights From the Odyssey Outcomes Trial (2020) (1)
Alirocumab and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: Prespecified Sub-analysis from ODYSSEY OUTCOMES. (2022) (1)
REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL (2019) (1)
Amended STRONG‐HF study design (2021) (1)
Ramipril Global Endpoint Trial / Telmisartan Randomized AssessmeNt Study in ACE withTelmisartan , Ramipril , or Both : The ONgoing Telmisartan Alone and in combination Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving (2010) (0)
Abstract 9193: Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial: Findings From ASCEND-HF (2012) (0)
Non-Q and 'incomplete-Q' myocardial infarction after thrombolysis is associated to reinfarction in a six-month follow-up (1999) (0)
METABOLIC RISK FACTORS AND THE EFFECT OF ALIROCUMAB ON CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROME: AN ANALYSIS OF THE ODYSSEY OUTCOMES RANDOMIZED CONTROLLED TRIAL (2021) (0)
Abstract 11173: Effect of Alirocumab on Peripheral Artery and Venous Thromboembolic Events, and Relation to Lipoprotein(a) Concentration (2019) (0)
Clinical significance of pseudonormalization of T waves during exercise ECG. Correlation with myocardial perfusion (1999) (0)
SHORT-DURATION, VERY HIGH-INTENSITY LIPID-LOWERING THERAPY RESULTS IN PROLONGED REDUCTION OF CARDIOVASCULAR EVENTS FOLLOWING ACUTE CORONARY SYNDROME (2023) (0)
Abstract 11898: Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia (2014) (0)
Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Randomized Trial. (2022) (0)
Abstract 104: First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study (2018) (0)
Treatment of acute myocardial infarction : Novel strategies based on old therapies (2001) (0)
Abstract 1535: Obesity Metrics And Their Associations With Type 2 Diabetes And Glucose Levels In A Large International Multi-ethnic Cohort. (2007) (0)
Selection of patients for angiography following myocardial infarction was not based on risk but on young age and availability of angiographic facilities. (1997) (0)
Abstract 10795: Alirocumab and Cardiovascular Outcomes in Older Patients After an Acute Coronary Syndrome: An ODYSSEY OUTCOMES Trial Analysis (2019) (0)
Abstract 14328: Relation of Lipoprotein(a) Levels to Incident Diabetes and Modification by Alirocumab Treatment: An Analysis of the Odyssey Outcomes Trial (2020) (0)
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial (2022) (0)
[Role of polypills in cardiovascular risk reduction in primary prevention]. (2022) (0)
Lipoprotein(a) and the Effect of Alirocumab on Revascularization Following Acute Coronary Syndrome. (2023) (0)
Abstract 16755: Association Between Achievement of Risk Factor Standard of Care Goals and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease in the STABILITY Trial (2015) (0)
Response to Letter Regarding Article, “Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction” (2010) (0)
Abstract 1305: Erectile Dysfunction Predicts Cardiovascular Events in High Risk Patients Receiving Telmisartan, Ramipril or Both (2009) (0)
ACHIEVEMENT OF NEW EUROPEAN DYSLIPIDEMIA-GUIDELINE LOW-DENSITY LIPOPROTEIN CHOLESTEROL TREATMENT GOALS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM ODYSSEY OUTCOMES (2020) (0)
EFFECT OF ALIROCUMAB ON FIRST AND TOTAL REVASCULARIZATIONS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME IN THE ODYSSEY OUTCOMES TRIAL (2020) (0)
Low-density lipoprotein cholesterol <50 mg/dL is an appropriate target after acute coronary syndrome: propensity score-matched analysis of the ODYSSEY OUTCOMES trial (2020) (0)
Abstract 11149: Effect of Low-density Lipoprotein Cholesterol Lowering With Alirocumab on Stroke in ODYSSEY OUTCOMES (2019) (0)
INSULIN, LIXISENATIDE, AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME (2020) (0)
Clopidogrel in Atrial Fibrillation: Is There Any Justification Now in the Era of New Anticoagulants? (2012) (0)
EFFECTS OF ALIROCUMAB IN PATIENTS WITH RECENT ACS AND A HISTORY OF HEART FAILURE: AN ANALYSIS OF THE ODYSSEY OUTCOMES TRIAL (2021) (0)
DYSGLYCEMIA, EJECTION FRACTION, AND THE RISK OF HEART FAILURE OR CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES AND A RECENT ACUTE CORONARY SYNDROME (2019) (0)
The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression (2013) (0)
Lower Mortality RAtes with TNK-tPA in Late-Treated Patients: REsults from the ASSENT-2 Study (2001) (0)
APOLIPOPROTEIN B, PCSK9 INHIBITION WITH ALIROCUMAB, AND ISCHEMIC CARDIOVASCULAR EVENTS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL (2020) (0)
Abstract 3680: Glucose Levels Predict Incident Cardiovascular Events In A Large International Multiethnic Cohort (2007) (0)
1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event (2020) (0)
Obesity Genes and Risk of Major Depression in a Multiethnic Population (2015) (0)
Usefulness of myocardial viability tests in the decision making process to indicate revascularization in patients with left ventricular dysfunction and coronary artery disease (2013) (0)
650 Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial: Findings From ASCEND-HF (2012) (0)
Abstract 3631: Elevated In-hospital Glucose Level, and not Known History of Diabetes Mellitus, Predicts 30-day Mortality Following Acute ST-elevation Myocardial Infarction (2007) (0)
Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES (2020) (0)
Pulmonary Function In Healthy Non-Smoking Adults From 17 Countries In Different Regions Of The World (2011) (0)
Abstract 14185: Heart Failure Occurring at any Time During Hospitalization is Associated with Higher Mortality in Non-ST Elevation-Acute Coronary Syndromes (2011) (0)
Contents (2020) (0)
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone (2022) (0)
POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES (2019) (0)
Prevalence,Awareness,Treatment,andControl ofHypertensioninRuralandUrbanCommunities inHigh-,Middle-,andLow-IncomeCountries (2013) (0)
LIPOPROTEIN(A) AND CARDIOVASCULAR OUTCOMES IN WOMEN AND MEN AFTER AN ACUTE CORONARY SYNDROME: A POST HOC ODYSSEY OUTCOMES TRIAL ANALYSIS (2023) (0)
STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone) People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in (2011) (0)
4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment (2019) (0)
Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome (2022) (0)
Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial (2022) (0)
EFFECTS OF ALIROCUMAB ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH PREVIOUS MYOCARDIAL INFARCTION: SUBANALYSIS FROM THE ODYSSEY OUTCOMES TRIAL (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Rafael Alfonso Figueroa Díaz?

Rafael Alfonso Figueroa Díaz is affiliated with the following schools:

Rafael Alfonso Figueroa Díaz's Academic­Influence.com Rankings

Rafael Alfonso Figueroa Díaz's Degrees

Why Is Rafael Alfonso Figueroa Díaz Influential?

Rafael Alfonso Figueroa Díaz's Published Works

Published Works

What Schools Are Affiliated With Rafael Alfonso Figueroa Díaz?

Rafael Alfonso Figueroa Díaz's AcademicInfluence.com Rankings